{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:17:47Z","timestamp":1761902267262,"version":"build-2065373602"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100015787","name":"Jiangsu Province Science and Technology Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015787","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.msard.2022.104127","type":"journal-article","created":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T23:48:15Z","timestamp":1660780095000},"page":"104127","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Different doses of Rituximab for the therapy of Neuromyelitis optica spectrum disorder: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"68","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7562-9514","authenticated-orcid":false,"given":"Kenhui","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianqian","family":"Nie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qun","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.msard.2022.104127_bib0001","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s00415-016-8188-y","article-title":"Rituximab in the treatment of Neuromyelitis optica: a multicentre Italian observational study","volume":"263","author":"Annovazzi","year":"2016","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.104127_bib0002","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.msard.2019.06.013","article-title":"Disease course, progression and activity of neuromyelitis optica (NMOSD) in patients who were treated with Rituximab, 6 and 12 months after receiving the first dose of drug, in Isfahan city","volume":"34","author":"Ashtari","year":"2019","journal-title":"Mult. Sclerosis Rel. Disord."},{"issue":"4","key":"10.1016\/j.msard.2022.104127_bib0003","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1007\/s00415-018-8771-5","article-title":"Treatment of neuromyelitis optica with rituximab: a 2-year prospective multicenter study","volume":"265","author":"Cabre","year":"2018","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2022.104127_bib0004","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.msard.2022.104127_bib0005","article-title":"Impact of Rituximab on relapse rate and disability in an Ecuadorian cohort of patients with neuromyelitis optica spectrum disorders","volume":"48","author":"Correa-D\u00edaz","year":"2021","journal-title":"Mult. Sclerosis Rel. Disord."},{"issue":"11","key":"10.1016\/j.msard.2022.104127_bib0006","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol."},{"issue":"1-2","key":"10.1016\/j.msard.2022.104127_bib0007","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jns.2015.10.036","article-title":"Rituximab in Turkish neuromyelitis optica patients with limited response to other immunosuppressants","volume":"359","author":"Erdener","year":"2015","journal-title":"J. Neurol. Sci."},{"issue":"10","key":"10.1016\/j.msard.2022.104127_bib0008","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/acn3.51451","article-title":"A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica","volume":"8","author":"Giovannelli","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2022.104127_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.clineuro.2020.106007","article-title":"Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder","volume":"196","author":"Gomez-Figueroa","year":"2020","journal-title":"Clin. Neurol. Neurosurg."},{"issue":"1","key":"10.1016\/j.msard.2022.104127_bib0010","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat. Rev. Dis. Prim."},{"issue":"3","key":"10.1016\/j.msard.2022.104127_bib0011","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1177\/1352458515587752","article-title":"Comparative analysis of treatment outcomes in patients with neuromyelitis optica spectrum disorder using multifaceted endpoints","volume":"22","author":"Jeong","year":"2016","journal-title":"Mult. Scl. (Houndmills, Basingstoke, England)"},{"issue":"11","key":"10.1016\/j.msard.2022.104127_bib0012","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1001\/archneurol.2011.154","article-title":"Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years","volume":"68","author":"Kim","year":"2011","journal-title":"Arch. Neurol."},{"issue":"11","key":"10.1016\/j.msard.2022.104127_bib0013","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2022.104127_bib0014","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1474-4422(20)30392-6","article-title":"New therapies for neuromyelitis optica spectrum disorder","volume":"20","author":"Levy","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2022.104127_bib0015","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.jneuroim.2017.12.021","article-title":"Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab","volume":"316","author":"Li","year":"2018","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2022.104127_bib0016","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ (Clin. Res. Ed.)"},{"key":"10.1016\/j.msard.2022.104127_bib0017","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jneuroim.2018.02.004","article-title":"Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder","volume":"317","author":"Lin","year":"2018","journal-title":"J. Neuroimmunol."},{"issue":"9","key":"10.1016\/j.msard.2022.104127_bib0018","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1093\/brain\/aww173","article-title":"Defining secondary progressive multiple sclerosis","volume":"139","author":"Lorscheider","year":"2016","journal-title":"Brain"},{"issue":"3","key":"10.1016\/j.msard.2022.104127_bib0019","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol."},{"issue":"9","key":"10.1016\/j.msard.2022.104127_bib0020","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2022.104127_bib0021","doi-asserted-by":"crossref","first-page":"311","DOI":"10.20517\/2347-8659.2020.05","article-title":"Clinical efficacy and safety of single cycle rituximab as induction therapy for aggressive neuromyelitis optica spectrum disorder in a resource limited center: a preliminary study","volume":"2020","author":"Ong","year":"2020","journal-title":"Neuroimmunol. Neuroinflamm."},{"issue":"5","key":"10.1016\/j.msard.2022.104127_bib0022","doi-asserted-by":"crossref","first-page":"732","DOI":"10.4103\/aian.AIAN_167_21","article-title":"Efficacy and safety of rituximab in central nervous system demyelinating disorders","volume":"24","author":"Patil","year":"2021","journal-title":"Ann. Indian Acad. Neurol."},{"issue":"2","key":"10.1016\/j.msard.2022.104127_bib0023","first-page":"155","article-title":"Efficacy and safety of rituximab in patients with refractory neuromyelitis optica spectrum disorders: A prospective observation in Iranian cases","volume":"11","author":"Seyed Ahadi","year":"2020","journal-title":"Caspian J. Int. Med."},{"issue":"3","key":"10.1016\/j.msard.2022.104127_bib0024","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1007\/s00415-019-09180-9","article-title":"Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study","volume":"266","author":"Shaygannejad","year":"2019","journal-title":"J. Neurol."},{"issue":"10206","key":"10.1016\/j.msard.2022.104127_bib0025","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1016\/S0140-6736(19)31878-1","article-title":"A new era for neuromyelitis optica spectrum disorder","volume":"394","author":"Silbermann","year":"2019","journal-title":"Lancet (London, England)"},{"issue":"8","key":"10.1016\/j.msard.2022.104127_bib0026","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","article-title":"Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response","volume":"88","author":"Stellmann","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.msard.2022.104127_bib0027","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2022.104127_bib0028","article-title":"Compassionate open-label use of rituximab following a randomised clinical trial against neuromyelitis optica (RIN-2 study): B cell monitoring-based administration","volume":"60","author":"Tahara","year":"2022","journal-title":"Mult. Sclerosis Rel. Disord."},{"issue":"7","key":"10.1016\/j.msard.2022.104127_bib0029","doi-asserted-by":"crossref","first-page":"e14158","DOI":"10.1111\/ijcp.14158","article-title":"The efficacy of rituximab in patients with neuromyelitis optica spectrum disorder: A real-world study from Turkey","volume":"75","author":"Uzunk\u00f6pr\u00fc","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"10.1016\/j.msard.2022.104127_bib0030","doi-asserted-by":"crossref","first-page":"642","DOI":"10.3389\/fneur.2020.00642","article-title":"Retrospective observation of low-dose rituximab treatment in chinese patients with neuromyelitis optica spectrum disorders in a real-world setting","volume":"11","author":"Xiao","year":"2020","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2022.104127_bib0031","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1212\/WNL.0b013e3182a1aac7","article-title":"Responsiveness to reduced dosage of rituximab in Chinese patients with neuromyelitis optica","volume":"81","author":"Yang","year":"2013","journal-title":"Neurology"},{"issue":"10","key":"10.1016\/j.msard.2022.104127_bib0032","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1007\/s00415-015-7852-y","article-title":"Rituximab as first-line therapy in neuromyelitis optica: efficiency and tolerability","volume":"262","author":"Z\u00e9phir","year":"2015","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.msard.2022.104127_bib0033","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1007\/s10072-021-05609-0","article-title":"Efficacy of azathioprine, mycophenolate mofetil, and rituximab in the treatment of neuromyelitis optica spectrum disorder and analysis of prognostic factors","volume":"43","author":"Zhang","year":"2022","journal-title":"Neurol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2022.104127_bib0034","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s13760-017-0795-6","article-title":"Effectiveness of low dose of rituximab compared with azathioprine in Chinese patients with neuromyelitis optica: an over 2-year follow-up study","volume":"117","author":"Zhang","year":"2017","journal-title":"Acta neurologica Belgica"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822006344?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034822006344?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T09:10:30Z","timestamp":1761901830000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034822006344"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":34,"alternative-id":["S2211034822006344"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2022.104127","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Different doses of Rituximab for the therapy of Neuromyelitis optica spectrum disorder: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2022.104127","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104127"}}